NLS Pharmaceutics (NLS Pharmaceutics) Total Liabilities : $10.68 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Total Liabilities?

NLS Pharmaceutics's Total Liabilities for the quarter that ended in Dec. 2023 was $10.68 Mil.

NLS Pharmaceutics's quarterly Total Liabilities increased from Dec. 2022 ($6.00 Mil) to Jun. 2023 ($6.56 Mil) and increased from Jun. 2023 ($6.56 Mil) to Dec. 2023 ($10.68 Mil).

NLS Pharmaceutics's annual Total Liabilities increased from Dec. 2021 ($5.22 Mil) to Dec. 2022 ($6.00 Mil) and increased from Dec. 2022 ($6.00 Mil) to Dec. 2023 ($10.68 Mil).

NLS Pharmaceutics Total Liabilities Historical Data

The historical data trend for NLS Pharmaceutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Total Liabilities Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

6.87

10.20

5.22

6.00

10.68

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial								5.22	6.10	6.00	6.56	10.68

NLS Pharmaceutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NLS Pharmaceutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.92	+	(0	+	-0.0010000000000002
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.5	+	0.261)
	=	10.68

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1.847	-	-8.834
	=	10.68

NLS Pharmaceutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.92	+	(0	+	-0.0010000000000002
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.5	+	0.261)
	=	10.68

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1.847	-	-8.834
	=	10.68

NLS Pharmaceutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.